TMEM109

Across TCGA pan-cancer cohorts, TMEM109 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TMEM109 data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM109 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM109 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, COAD, and PDAC are the cancer types where TMEM109 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.733	0.525	.005	14	view →
COAD	DFS	Median	III,IV	0.829	1.000	.027	12	view →
PDAC	DFS	Tertile	II,III,IV	0.366	0.621	.014	9	view →
GBM	OS	Median	All	0.289	0.521	.012	5	view →
LSCC	OS	Quartile	II,III,IV	0.605	0.948	.007	3	view →
LUAD	OS	Quartile	II,III,IV	0.863	0.467	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TMEM109–HNSC (DFS)

Open the HNSC breakdown →